RV

Remiges Ventures

North America, Massachusetts, United States, Cambridge

Description

Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.

Investor Profile

Remiges Ventures has backed more than 18 startups, with 2 new investments in the last 12 months alone. The firm has led 12 rounds, about 67% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Seed rounds (top funding stages).
  • Majority of deals are located in United States, Japan, Germany.
  • Strong thematic focus on Biotechnology, Therapeutics, Health Care.

Stage Focus

  • Series A (44%)
  • Series B (28%)
  • Seed (17%)
  • Series C (11%)

Country Focus

  • United States (44%)
  • Japan (22%)
  • Germany (17%)
  • Israel (6%)
  • France (6%)
  • Canada (6%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science
  • Pharmaceutical
  • Medical Device
  • Clinical Trials
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Remiges Ventures frequently co-invest with?

Abingworth
Europe, England, United Kingdom, London
Co-Investments: 2
CV
North America, Massachusetts, United States, Boston
Co-Investments: 2
SMBC Venture Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
ANRI
Asia, Tokyo, Japan, Tokyo
Co-Investments: 3
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 2
QB Capital
Asia, Fukuoka, Japan, Fukuoka
Co-Investments: 2
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 3
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
Kyoto University Innovation Capital
Asia, Kyoto, Japan, Kyoto
Co-Investments: 2
UntroD Capital
Asia, Tokyo, Japan, Sumida
Co-Investments: 2

What are some of recent deals done by Remiges Ventures?

Glycomine

San Francisco, California, United States

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

BiotechnologyPharmaceuticalTherapeutics
Series CApr 16, 2025
Amount Raised: $115,000,000
KisoJi Biotechnology

Laval-ouest, Quebec, Canada

KisoJi Biotechnology is a biotechnology company focused on healthcare and life sciences for research and development industries.

BiotechnologyLife ScienceMedicalTherapeutics
Series BDec 2, 2024
Amount Raised: $40,579,533
Cyrano Therapeutics

Washington, District of Columbia, United States

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.

Health CareMedicalMedical DeviceTherapeutics
Series BJan 16, 2024
Amount Raised: $9,000,000
Restore Vision

Tokyo, Tokyo, Japan

Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.

BiotechnologyHealth CareTherapeutics
Series ADec 15, 2023
Amount Raised: $4,221,636
Restore Vision

Tokyo, Tokyo, Japan

Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.

BiotechnologyHealth CareTherapeutics
Series AJun 5, 2023
Amount Raised: $9,109,510
Kupando

Schönefeld, Brandenburg, Germany

Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.

Biotechnology
Series ASep 26, 2022
Amount Raised: $12,506,073
LUCA Science

Tokyo, Tokyo, Japan

LUCA Science develops innovative treatments intended for mitochondrial and related diseases.

BiotechnologyHealth CarePharmaceutical
Series BJun 6, 2022
Amount Raised: $29,203,600
Restore Vision

Tokyo, Tokyo, Japan

Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.

BiotechnologyHealth CareTherapeutics
SeedFeb 3, 2022
Amount Raised: $2,566,121
Viage Therapeutics

San Francisco, California, United States

Viage Therapeutics is a biotech company that develops therapeutics that stimulates the central nervous system via the gut-brain axis.

BiotechnologyClinical TrialsMedical
SeedJan 6, 2022
Amount Raised: $10,000,000
Capacity Bio

Palo Alto, California, United States

Capacity Bio is a therapeutics company that is focused on mitophagy.

BiotechnologyLife ScienceMedical
SeedJan 1, 2022

Find More Investors Like Remiges Ventures

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides